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tyrosine kinase, then IFN--y and GM-CSF
would have different pathways of action.
The regulation of macrophage activation
by GM-CSF provides a mechanism whereby
T lymphocytes, in response to antigen, may
regulate a nonspecific effector function of
macrophages in the absence of any require-
ment for an exogenous signal provided by
bacterial products. This may therefore repre-
sent an important pathway of antitumor
defense.
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The Neuroendocrine Thymus: Coexistence of
Oxytocin and Neurophysin in the Human Thymus
VINCENT GEENEN, JEAN-JACQUES LEGROS, PAUL FRANCHIMONT,
MARc BAUDRIHAYE, MARIE-PAULE DEFRESNE, JACQUES BONIVER
Immunoreactive oxytocin and neurophysin were identified and measured by radioim-
munoassay in human thymus extracts. Serial dilutions of extracts paralleled the
appropriate standard curves. Thymus-extracted oxytocin and neurophysin eluted in
the same positions as reference preparations on Sephadex G-75. Authenticity of
oxytocin was confirmed by biological assay and high-performance liquid chromatogra-
phy analysis. In most instances, thymus contents ofoxytocin and neurophysin were far
greater than those expected from known circulating concentrations and declined with
increasing age. The molar ratio of oxytocin to neurophysin in thymus was similar to
that found in the hypothalamo-neurohypophyseal system, which strongly suggested
with the other data a local synthesis ofoxytocin. These findings indicate the presence of
neurohypophyseal peptides in the human thymus and further support the concept ofa
neuroendocrine function integrated in an inmune structure.
R ECENT STUDIES HAVE PROVIDED
evidence of reciprocal interactions
between the neuroendocrine and
immune systems (1). In this respect, thymic
hormones, besides their known immunolog-
ical properties, have been found to modulate
some important hypothalamo-hypophyseal
functions (2). In the thymus, distinct cell
populations have been identified through
the use ofmonoclonal antibody A2B5, which
recognizes a complex ganglioside expressed
on the membrane of neurons and neural
crest-derived and neuropeptide-secreting
endocrine cells (3). The thymus contains
mesenchymal cells, probably of neural crest
origin; the development of thymic epitheli-
um may depend on induction by neural crest
mesenchyme (4). To our knowledge, the
presence of neurohormones in the thymus
has not been systematically investigated un-
til now.
Oxytocin is a 1000-dalton nonapeptide
synthesized in hypothalamic magnocellular
neurons as a large molecular weight precur-
sor which is then cleaved during axonal
transport into oxytocin and a 10,000-dalton
oxytocin-related carrier protein, neurophy-
sin (5). The main physiological actions of
oxytocin in mammals are the stimulation of
milk ejection and uterus contractions. Oxy-
tocin and neurophysin are widely distribut-
ed in the central nervous system (6) and in
peripheral organs such as ovary, testis, and
adrenal medulla (7). These data led us to
investigate the presence of oxytocin and
neurophysin in the human thymus.
Thymus tissues were obtained from six
patients undergoing cardiovascular or tho-
racic surgery for different reasons (Table 1):
therapeutic thymectomy for myasthenia gra-
vis (patient 1), coronary bypass (patients 2
and 3), anterior mediastinal mass (patient
4), and congenital heart disease (patient 5).
One thymus was excised at autopsy of a
newborn who died after acute respiratory
distress (patient 6). Care was taken to obtain
thymuses from patients in early childhood
to advanced adult age; no other selection
method was used. In most cases, thymic
fragments were histologically analyzed (Ta-
ble 1). The anterior mediastinal mass was
found to be a thymoma (patient 4). In
patient 1, further routine immunohistologi-
cal analyses revealed a normal distribution of
lymphoid phenotypes Leu-1 to Leu-4.
Thymic specimens were weighed, finely
minced in a dish on crushed ice, and homog-
enized by sonication in 0.4M acetic acid at
4°C (1 ml per 100 mg of tissue). Homoge-
nates were centrifuged at 13,000g for 20
minutes at 4°C; then supernatants were sep-
arated and filtered to remove insoluble parti-
cles. When mentioned further, the term
"crude extract" will refer to this preparation
step. An additional extraction procedure
was carried out before we measured immu-
noreactive or biological activities and sub-
jected the extract to high-performance liquid
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chromatography (HPLC): 2-ml portions of
crude extract equivalent to 0.2 g of tissue
were subjected to gel filtration on a Sepha-
dex G-25 column (0.9 x 30 cm) eluted at
4°C in 0.1M ammonium acetate atpH 6.8.
Fractions of 1 ml corresponding to the
elution volume of synthetic oxytocin (frac-
tions 13 to 20) were pooled, lyophilized,










Fig. 1. Oxytocin immunore-
activity of serial dilutions of
human thymus extracts
compared with the oxytocin
standard curve. The ordi-
nate shows bound 125I-la-
beled oxytocin (B) expressed
as the percentage of 12I-
labeled oxytocin bound in
the absence ofsynthetic oxy-
tocin (Bo). The points on
the standard curve are given




Table 1 shows the amounts ofimmunore-
active oxytocin and neurophysin detected in
human thymus extracts by specific radioim-
munoassays (8, 9). Thymic oxytocin content
was particularly high in patient 1 when
compared with the other patients; in general
the oxytocin concentration of the thymus
declined with increasing age of the patient.
In thymus extracts 2 to 6, the mean molar
ratio of oxytocin to neurophysin was
1.1 ± 0.2 (SEM). This ratio was clearly
higher in the thymus extract 1, so it was
excluded from the global mean.
Figure 1 illustrates the parallelism ob-
served between the oxytocin standard curve
and the displacement curves produced by
serial dilutions of three separate thymus
extracts. Similar curves were obtained with
the extracted neurophysin immunoreactiv-
ity.
An extract of thymus 1 was tested for
oxytocin biological activity by an assay with
isolated rat uterus (10). A uterine contrac-
tion that was typical of oxytocin occurred
with an estimated oxytocin-like bioactivity
of4.5 mIU (corresponding to 7.7 ng ofthe
Fourth International Oxytocin Standard
used as reference). This value was in quanti-
tative agreement with the amount detected
by radioimmunoassay (7.1 ng per 0.2 g of
extracted tissue).
Figure 2 shows the results from Sephadex
G-75 chromatography of the thymus crude
extracts 5 and 6. In both cases, separate
peaks of oxytocin and neurophysin immun-
oreactivities were evidenced in the same
positions as their respective reference prepa-
rations. A discrete peak of immunoreactive
oxytocin was also coeluted in fractions ofthe
ascending part of the neurophysin peaks.
Further characterization of the thymic
oxytocin-like peptide was determined by
HPLC analysis of thymus extracts 3 and 6
(Fig. 3). In each case, a single peak of
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Fig. 2 (left). Sephadex G-75 elution profiles of neurophysin (0) and
oxytocin (O) immunoreactivities of two separate thymus crude extracts.
Four milliliters of samples 5 (---) and 6 (-) were applied to a column of
Sephadex G-75 (medium, Pharmacia, 0.9 by 60 cm) and eluted at 4°C in
O.lM formic acid with a flow rate of 15 ml/hour. Fractions of 1 ml were
collected, lyophilized, and assessed for oxytocin and neurophysin immuno-
reactivities. Synthetic oxytocin and purified bovine oxytocin-associated
neurophysin (bNp I) were used as reference preparations and chromato-
graphed in identical conditions. Fig. 3 (right). HPLC elution profiles of
oxytocin immunoreactivity of thymus extracts 3 (0) and 6 (0) after
prelimninary Sephadex G-25 filtration. HPLC system (Waters Associates)
25 APRIL I986
consisted of a solvent delivery system (model 6000 A), a microprocessor-
based system controller (model 720) and a variable wavelength detector. The
column used was a 10-,um Bondapak C-18 (0.39 x 30 cm). Elution was
performed in 1% trifluoroacetic acid, and a linear gradient from 0 to 60%
acetonitrile was applied for 90 minutes with a flow rate of 1 ml/min.
Fractions of 1 ml were collected, lyophilized, and assayed for oxytocin
immunoreactivity. The positions of standard peptides oxytocin, argmine-
vasopressin (AVP), and arginine-vasotocin (AVT) were determined by













































































Table 1. Clinical characteristics, thymus histological analyses, and immunoreactive oxytocin and
neurophysin contents. Reproducibility of the assays was tested for samples 1 and 5; mean coefficients of
variation were in the range of values previously reported for oxytocin and neurophysin assays (8, 9)-
14.7 and 16.8%, respectively. Mean molar ratio of oxytocin:neurophysin for patients 2 to 6 was
1.1 ± 0.2. Human blood concentrations reported for oxytocin and neurophysin are 0.3 to 6.7 pg/mil
(11) and 0.1 to 7.5 ng/ml (9), respectively.
Patient Thymus
Oxy- Neuro- Oxytocin:
Num- A~ge Sextocin physi neuro-ber (years) Sex Diagnosis Histology (ng/g (ng/g physin
wet wet physin
weight) weight) mrlar
1 26 M Myasthenia gravis Normal 35.5 52 6.8
2 51 M Coronary bypass Normal (adipose 2.2 24 0.9
involution)
3 31 M Coronary bypass Normal (partial adi- 3.4 27 1.2
pose involution)
4 52 F Anterior media- Thymoma 1.5 19 0.8
stinal mass
5 8 M Ductus Normal 10.5 142 0.7
arteriosus
6 1 M Acute respiratory Not examined 18.4 94 1.9
distress
running in the same elution site as authentic
oxytocin.
Altogether, these data show the presence
in the human thymus of a peptide sharing
biological, immunological, and physico-
chemical properties with authentic oxytocin.
A neurophysin immunoreactivity was also
reported, usually with a molar ratio of oxy-
tocin:neurophysin analogous to that found
(1:1) in the hypothalamus. Thymic contents
of oxytocin and neurophysin were consider-
ably higher than those expected from the
previously reported human blood concen-
trations: 0.3 to 6.7 pg/ml for oxytocin (11)
and 0.1 to 7.5 ng/ml for neurophysin (9).
The coexistence of high equimolar amounts
of oxytocin and neurophysin in the human
thymus strongly suggests a local biosynthe-
sis by cleavage from a common precursor as
demonstrated in the hypothalamus (5). Also
supporting this hypothesis was the coelu-
tion of some oxytocin immunoreactivity at
the start of the neurophysin peaks during
Sephadex G-75 chromatography (Fig. 2),
which may indirectly reflect the presence of
such a larger precursor in the thymus. In
fact, the high concentrations of immunore-
active neurophysin in the thymic gland
would be difficult to explain if this organ
were just a target for the circulating neuro-
hypophyseal peptides since peripheral recep-
tors to neurophysin have not been de-
scribed. Moreover, such a peripheral biosyn-
thesis of oxytocin has already been demon-
strated in the bovine corpus luteum (12).
The myasthenic patient constituted an
exception, with a molar ratio of oxytocin to
neurophysin far greater than the theoretical
one. The intrathymic oxytocin content was
particularly high in this patient compared
with other patients, but we do not know the
physiopathological reason for this finding.
Numerous abnormalities have been de-
scribed in thymuses of myasthenic patients,
including thymoma (13) (which was not
detected in our patient), activation of thy-
mic B lymphocytes (14), and an excess of
myoid cells bearing acetylcholine receptors
(15). Related or not, the high oxytocin
content in the thymus of a myasthenic pa-
tient raises several questions for further in-
vestigations.
The nature of oxytocin-producing cells in
thymus is still to be determined, but some
hypotheses may be advanced on the basis of
recent reports. Lymphocytes produce adren-
ocorticotropin- and endorphin-like sub-
stances, two polypeptides also coordinately
synthesized in the anterior pituitary as a
large molecular weight precursor, as well as
immunoreactive thyroid-stimulating hor-
mone and human chorionic gonadotropin
(16). Thus, the production of oxytocin and
associated neurophysin by thymocytes must
be regarded as plausible. Another possibility
is that some thymic stromal cells derived
from the neural crest are the oxytocin- and
neurophysin-secreting cells. This suggestion
would be more appropriate with regard to a
proper neuroendocrine function of the thy-
mus. Immunohistological studies with the
use of antibodies to oxytocin and monoclo-
nal A2B5 antibodies used conjunctively are
needed to clarify this point.
The physiological meaning of the pres-
ence of oxytocin-related peptides in human
thymus is still unknown. It is tempting to
speculate that thymocytes could be the tar-
gets for oxytocin. Both vasopressin and oxy-
tocin have replaced interleukin-2 (the T-cell
growth factor) for y-interferon production
by Lyt 2+ mouse lymphocytes (17). Al-
though the neurohypophyseal peptides are
not directly mitogenic for peripheral lym-
phocytes [(17) and personal observationsl,
vasopressin stimulates DNA synthesis in
bone marrow cells (18). Recently the role of
several neuropeptides in the control of cell
proliferation has been suggested (19). Final-
ly, oxytocin was reported to stimulate glu-
cose oxydation in rat thymocytes (20).
Therefore, some comitogenic, inductive, or
repressive actions ofthymic oxytocin during
thymocyte differentiation are attractive spec-
ulations deserving of future investigation.
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Receptor-Associated Resistance to Growth Hormone-
Releasing Factor in Dwarf "Little" Mice
JOHN-OLOV JANSSON, THOMAS R. DowNs, WESLEY G. BEAMER,
LAWRENCE A. FROHmAN*
Anterior pituitaries from the dwarf mouse strain "little" did not release growth
hormone or accumulate adenosine 3',5'- monophosphate (cyclic AMP) in response to
human and rat growth hormone-releasing factor (GRF). Dibutyryl cyclic AMP, as
well as the adenylate cyclase stimulators forskolin and cholera toxin, markedly
stimulated growth hormone (GH) release. The basis of the GH deficiency in the little
mouse may therefore be a defect in an early stage of GRF-stimulated GH release
related either to receptor binding or to the function ofthe hormone-receptor complex.
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Fig. 1. Effect ofhGRF on GH releast
lit/lit and normal +/lit pituitary cells
hour incubation. Each point represet
SEM of four to eight observation
response curve of +/lit mice was ana
ALLF1T program (22). Results are
from two separate experiments. Fill(







of these patients (1). Such a defect could be
attributed to impaired GRF synthesis, re-
lease, or transport or to insensitivity of the
somatotrophs to GRF.
nvolve only The recessive autosomal little (lit) muta-
or may be tion in mice results in decreased growth and
other pitu- partial GH deficiency. It has been suggested
ilogical and that the little mouse represents a useful
taries from model for isolated human GH deficiency,
iency have especially the inherited isolated GH defi-
)f GH syn- ciency type I (3). We now report that pitu-
that stimu- itaries of little mice are completely insensi-
alamic GH- tive to GRF, and we address the cellular
yve in many basis for this phenomenon.
Homozygous 60- to 80-day-old female
little mice (lit/lit) were compared with their
heterozygous litter mates (+/lit), which are
phenotypically identical to normal C57
BL/6J (+/+) mice. Anterior pituitaries were
dissociated (4) and cultured for 3 days be-
fore being used. The yield from lit/lit and
+/lit mice ranged from 0.45 to 0.5 x 106
and 1.2 to 1.4 x 106 cells per pituitary,
respectively. Mouse GH was measured by a
rat GH radioimmunoassay (RIA) (5).
lit/lit The little mouse (lit/lit) pituitary con-
Tf7M z tained only 9 percent ofthe normal concen-
tration of GH in heterozygotes [902 + 25
ng (mean ± SEM) compared with
9748 ± 298 ng per 105 cells], confirming
'0 previous observations (3). Incubation of
+/lit pituitary cells with human GRF (1-
from dwarf 40)-OH (hGRF) at 300 to 1000 nM for 4
during a4a hours stimulated GH secretion by a factor of
nts the mean six (Fig. 1). The half-maximal stimulatory
Is. The dose- concentration (EC5o) of hGRF, was 6 nM.
dyzed by the In contrast, pituitary cells from lit/lit mice
pooled data did not respond to hGFR, even at a concen-
ed 2, respec- tration (1000 nM) that was more than 100
times that of the EC50 for +llit pituitaries.
These results are supported by the observa-
tion that anesthetized little mice do not
release GH in response to the intravenous
injection of a GRE fragment (6).
Exposure of +llit pituitary cells to hGRF
for 24 hours also caused a dose-dependent
stimulation ofGH release (Table 1), where-
as GH secretion from litllit somatotrophs
remained unaffected. Human GRF in-
creased total GH (medium + cells) in cul-
tures of +11it but not lit/lit somatotrophs.
These results suggest that hGRF-stimulated
transcription of the GH gene and subse-
quent GH synthesis (7) does not occur in
lit/lit pituitaries.
We next examined the cellular mecha-
nisms responsible for the absence of GRF
responsiveness in litliit pituitaries. GRF in-
duces a rapid increase in intracellular adeno-
sine 3',5'-monophosphate (cyclic AMP)
concentrations, which seems to mediate the
hormone's effects on GH synthesis and re-
lease (8,9). Human GRF had a pronounced
dose-related effect on cyclic AMP accumula-
tion in pituitary cells from +/lit but not
lit/lit mice (Fig. 2). The absence of increased
= 0.5
_ lit/lit





Fig. 2. Effect of hGRF on intracellular cAMP
levels as measured by RIA (23) in pituitary cells
from +/lit and lit/lit mice. Incubations were of 4
hours' duration. Results are the mean ± SEM of
four observations.
cclic AMP concentrations in lit/lit somato-
trophs may therefore constitute an etiologi-
cal factor in the lack of GH response to
GRF. To test this possibility, we investigat-
ed the effects of a cyclic AMP analog and
stimulators of the adenylate cyclase (AC)-
cyclic AMP system other than GRF. Dibu-
tyryl cyclic AMP induced a dose-related
increase in GH secretion from +/lit as well
as lit/lit pituitaries (Fig. 3). Forskolin, a
plant diterpene capable of stimulating the
catalytic subunit (C) ofthe AC system in the
absence of the regulatory subunit (Gs) (10),
stimulated GH secretion in lit/lit and +/lit
cultures. Cholera toxin, an agent that in-
J.-O. Jansson, T. R. Downs, L. A. Frohman, Division of
Endocrinology and Metabolism, University of Cincin-
nati College of Medicine, Cincinnati, OH 45267.
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